Daniel Jeffrey Wallace (born October 27, 1949) is an American rheumatologist, clinical professor, author, and fellow.[1] Wallace has published 500 peer reviewed publications, 9 textbooks, and 28 book chapters on topics such as lupus, Sjögren syndrome, osteoarthritis, and fibromyalgia.[2] He has the largest cohort of lupus patients in the United States (2000).[3] A full professor of medicine (Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA), he is associate director of the Rheumatology Fellowship Program at Cedars-Sinai.[4] His seminal contributions to research include being an author of the first paper to demonstrate vitamin D dysfunction[5] and the importance of interleukin 6 in lupus,[6] conducting the first large studies of apheresis in rheumatoid arthritis and lupus,[7] and insights into the mechanisms of action of antimalarials.[8] Wallace's research accomplishments also include conducting many clinical rheumatic disease trials, examining the role of microvascular angina[9] and accelerated atherogenesis in lupus,[10] and work on anti-telomere antibodies which have garnered him 6 papers in The New England Journal of Medicine. Wallace's monograph, The Lupus Book, has sold over 100,000 copies since 1995.[11]
Wallace has written 9 textbooks on autoimmune diseases such as lupus, fibromyalgia, osteoarthritis, and Sjögren syndrome. Wallace has authored 28 book chapters and supplements on these same topics. Wallace has also written 500 peer-reviewed manuscripts.[2] He has been the recipient of NIH and Department of Defense grants.[18]
Charitable work
Wallace and Adam Selkowitz founded Lupus LA, an organization that raises money for Lupus research and patient care.[19] Wallace served on the Medical Executive Committee for the American Society for Apheresis from 1987-1989.[16] He was Co-Chairman (1999-2000) and Vice President (1999-2000) the Lupus Foundation of America and served on the National Medical Advisory Board.[16] He now serves on the Board of Directors of the Lupus Research Alliance, Lupus Therapeutics, and the Sjogren's Foundation.[20] Wallace served as Chairman of the Research and Education Foundation of the American College of Rheumatology.[16] Wallace was on the Board of Directors of the Lupus Research Institute.[16] Wallace was also on the Board of Directors for the United Scleroderma Foundation from 2001-2004.[16]
^Linker-Israeli, M.; Elstner, E.; Klinenberg, J.R.; Wallace, D.J.; Koeffler, H. P. (2001). "Vitamin D3 and its Synthetic Analogs Inhibit the Spontaneous in Vitro Immunoglobulin Production by SLE-Derived PBMC". Clinical Immunology. 99 (1): 82–93. doi:10.1006/clim.2000.4998. PMID11286544.
^Wallace, Daniel J.; Goldfinger, Dennis; Thompson-Breton, Ranee; Martin, Vincent; Lowe, Cheryl M.; Bluestone, Rodney; Klinenberg, James R. (1980). "Advances in the use of therapeutic pheresis for the management of rheumatic diseases". Seminars in Arthritis and Rheumatism. 10 (2): 81–91. doi:10.1016/0049-0172(80)90001-3. PMID7292020.
^Wallace, Daniel J. (2008). "Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?". Nature Clinical Practice Rheumatology. 4 (9): 450–451. doi:10.1038/ncprheum0876. PMID18665150. S2CID8272289.